You are here: Industry Insights > Bayer

News List

Chasing Pfizer and J&J, Bayer’s Nubeqa nabs fast FDA nod in prostate cancer biospectrumasia
August 01, 2019
Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada may have big head starts in the prostate cancer market, but Bayer and partner Orion have a new entry—and they're looking to carve out a share.
Orion and Bayer secure FDA approval for prostate cancer drug pharmaceutical-technology
August 01, 2019
Orion and Bayer have obtained the US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide) to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
Roche, like Bayer, was hit in Winnti cyberattack fiercepharma
July 28, 2019
It turns out that Bayer was not the only pharma company targeted by the Winnti cyberattack believed to have been instituted by hackers tied to the Chinese government. Roche also was a victim.
Two lots of Kogenate® recalled due to mislabelling europeanpharmaceuticalreview
July 25, 2019
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
Bayer Recalls Two Lots of Kogenate® FS Antihemophilic Factor americanpharmaceuticalreview
July 24, 2019
Bayer is voluntarily recalling two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level.
Bayer, BMS, Ono Pharma enter into clinical collaboration for colorectal cancer biospectrumasia
July 22, 2019
Under clinical collaboration agreement companies to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
Bristol-Myers Squibb, Bayer team up on Opdivo-Stivarga combo in colorectal cancer fiercepharma
July 20, 2019
Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.
Bayer, Bristol-Myers Squibb, Ono Pharmaceutical to Investigate Stivarga, Opdivo Combo Therapy americanpharmaceuticalreview
July 19, 2019
Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical announced the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga® (regorafenib) and ...
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement worldpharmanews
July 19, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement.
Bayer, BMS, Ono to Collaborate on Colorectal Cancer Treatments contractpharma
July 19, 2019
Aims to evaluate the combination of Bayer's Stivarga and BMS / Ono's Opdivo in patients with MSS mCRC.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page